Medline (MDLN)

Medline, represented by the symbol MDLN-Q, has shown a promising start since its IPO last month, registering a remarkable 39.4% increase. Despite some volatility, the company's performance appears robust compared to many IPOs from the previous year. Having gone public recently, Medline reported a 9.8% growth in net sales and an impressive 12.9% adjusted EBITDA margin during the first three quarters of 2025. While boasting notable sales growth in recent years, the company has a reasonable, if not stellar, balance sheet. Prospective buyers should be cautious, as existing shareholders retain 80% of voting power, making the shares appear rich with a steep valuation of approximately 45x PE, especially given its low double-digit growth rate. Experts suggest waiting for a more favorable entry point around $29-30.